Article Text

other Versions

PDF
Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up
  1. Rene Antonio Cervantes-Castañeda1,2,
  2. Luis Alonso Gonzalez-Gonzalez1,3,
  3. Miguel Cordero-Coma1,4,
  4. Taygan Yilmaz1,5,
  5. C Stephen Foster1,3,6
  1. 1Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA
  2. 2CODET Vision Institute, Ocular Inflammatory Disease Department, Tijuana, Mexico
  3. 3Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts, USA
  4. 4Uveitis Unit, Department of Ophthalmology, Hospital de Leon, León, Spain
  5. 5Stony Brook Medical Center, New York, New York, USA
  6. 6Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr C Stephen Foster, Massachusetts Eye Research and Surgery Institution, 5 Cambridge Center, 8th Floor, Cambridge, MA 02142, USA; fosters{at}uveitis.org

Abstract

Purpose To retrospectively report a 12-month follow up for combined therapy with systemic cyclosporine A (CSA) and mycophenolate mofetil (MM) in treatment of patients with birdshot retinochoroidopathy (BSRC).

Participants Ninety-eight eyes of patients who received CSA and MM for the treatment of BSRC were included in the study.

Methods All patients were followed for at least five visits during the study, or until treatment failure, or loss of follow-up. Clinical data were analysed using a Student paired t-test, Wilcoxon signed-rank test, McNemar's test, and Kaplan -Meier survival curve. Side effects related to therapy were also recorded. Main outcome measures included best-corrected logarithm of the minimum angle of resolution visual acuity, vitreous inflammation, fluorescein angiography pathologic features, and electroretinogram recordings.

Results Vitreous inflammation scores at baseline and at 1 year were statistically significantly reduced in both eyes (p<0.001; p=0.001). The presence of angiographic leakage at the 1-year follow-up was significantly reduced (p=0.004). However, the presence of cystoid macular oedema (p=0.32) and comparison of electroretinogram 30-Hz amplitude revealed no significant reduction between baseline and 1-year values for either eye (p=0.61, p=0.87); nonetheless, 30-Hz implicit times were statistically significantly shorter at the end of follow-up for both eyes (p<0.001, p=0.035). Thirty-one patients (67.4%) achieved inflammation control at the 1-year endpoint. Side effects were transient, and resolved after lowering or withholding IMT for a few weeks in the majority of patients.

Conclusions These results suggest that combined IMT with CSA and MM for BSRC is well tolerated and associated with long-term control of inflammation.

  • Immunology
  • Inflammation
  • Pharmacology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.